+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Autoimmune Disease Drugs Market by Drug Class, Mechanism of Action, Route of Administration, Indication, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Autoimmune Disease Drugs Market by Drug Class, Mechanism of Action, Route of Administration, Indication, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Sale

Autoimmune Disease Drugs Market by Drug Class, Mechanism of Action, Route of Administration, Indication, End User, Distribution Channel - Global Forecast 2026-2032

  • Report

  • 199 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904622
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Autoimmune Disease Drugs Market is projected to reach USD 135.64 Billion in 2026. It is expected to continue growing at a CAGR of 8.45%, reaching USD 222.19 Billion by 2032.

The autoimmune disease drugs market is anchored by chronic, immune-mediated conditions such as rheumatoid arthritis, psoriasis, psoriatic arthritis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, type 1 diabetes, and autoimmune thyroid disorders. More than 80 autoimmune diseases are recognized in medical literature, and many require long-term pharmacologic management, creating sustained demand for immunosuppressants, corticosteroids, conventional disease-modifying antirheumatic drugs, biologics, biosimilars, and targeted small molecules.

Market momentum is being shaped by earlier diagnosis, expanding specialist access, rising use of treat-to-target protocols, and continued innovation in cytokine inhibition, B-cell modulation, T-cell pathways, complement inhibition, Janus kinase inhibition, sphingosine-1-phosphate receptor modulation, and emerging Bruton tyrosine kinase inhibitors. At the same time, payer pressure, biosimilar competition, safety monitoring, and real-world evidence requirements are redefining how autoimmune disease drugs are developed, priced, prescribed, and reimbursed.

Transformative Shifts in the Autoimmune Treatment Landscape

The autoimmune treatment landscape is moving from broad immune suppression toward precision immunology, where therapies are increasingly selected according to disease phenotype, biomarker profile, prior treatment response, comorbidity risk, and route-of-administration preference. Biologics remain central in high-value autoimmune therapy categories, while biosimilars are reshaping competition in established segments such as tumor necrosis factor inhibitors and other monoclonal antibody classes.

Transformative shifts include stronger adoption of self-injectable and oral targeted therapies, growing post-marketing safety oversight for JAK inhibitors and other immunomodulators, and rising payer demand for comparative effectiveness evidence. Manufacturers are also adapting to decentralized clinical trials, patient support programs, specialty pharmacy models, and value-based contracting, all of which influence market access, adherence, and brand durability.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value across autoimmune disease drug discovery, clinical development, commercialization, and pharmacovigilance. AI-enabled analytics can identify immune pathway targets, mine genomic and proteomic datasets, model disease progression, and support patient stratification in heterogeneous conditions such as systemic lupus erythematosus, inflammatory bowel disease, psoriasis, rheumatoid arthritis, and multiple sclerosis.

The strongest impact is emerging where AI improves trial feasibility, enriches responder populations, accelerates safety signal detection, and converts real-world data into actionable evidence for regulators, payers, clinicians, and patients. Responsible adoption requires transparent models, bias assessment, data privacy controls, and clinical validation, particularly because autoimmune diseases disproportionately affect women and often present with variable symptoms across ancestry groups, age cohorts, and care settings.

Key Regional Insights

North America remains a leading region for autoimmune disease drugs due to strong specialty care infrastructure, advanced biologic use, FDA innovation pathways, and broad clinical trial activity, with the United States driving most regional demand and Canada emphasizing structured reimbursement review. Europe combines high diagnosis rates, EMA oversight, established clinical guidelines, and mature health technology assessment systems, while biosimilar adoption is particularly important in cost containment across major European Union markets and the United Kingdom.

Asia-Pacific is expanding rapidly as China, Japan, India, South Korea, and Australia invest in biologics, biosimilars, local manufacturing, clinical research capacity, and broader access to specialty medicines. Latin America, led by Brazil and Mexico, is improving access through public procurement and private insurance channels, although affordability, reimbursement consistency, and specialist availability remain constraints. The Middle East, especially GCC markets, is increasing biologic uptake through hospital modernization, national health strategies, and specialty care investment, while Africa continues to face access gaps linked to diagnostic capacity, rheumatology and immunology specialist shortages, cold-chain limitations, and reimbursement constraints.

Key Group Insights

The G7 continues to anchor high-value autoimmune drug innovation through advanced research ecosystems, experienced regulatory agencies, strong pharmacovigilance systems, and large specialty pharmaceutical markets. The European Union plays a central role in biosimilar policy, centralized approvals, health technology assessment alignment, real-world evidence standards, and cross-border pharmacovigilance, supporting both innovation and cost efficiency across member states.

BRICS countries are increasingly important for patient access expansion, local biologics production, biosimilar development, and clinical trial diversification, with China, India, and Brazil standing out for scale and manufacturing capacity. ASEAN markets are progressing through broader healthcare coverage, improving diagnostic pathways, and better specialist access, although reimbursement depth varies widely across member countries. GCC countries are investing in premium care infrastructure, digital health, biologic access, and centralized procurement capabilities, while NATO is not a healthcare market bloc but includes countries prioritizing medicine supply resilience, procurement security, emergency preparedness, and biopharmaceutical manufacturing continuity.

Key Country Insights

The United States is the largest commercial opportunity within autoimmune disease drugs, supported by specialist prescribing, biologic penetration, rapid uptake of novel therapies, robust clinical trial participation, and extensive real-world evidence generation, while Canada emphasizes evidence-based reimbursement, health technology review, and provincial formulary access. Mexico and Brazil are expanding autoimmune treatment capacity but remain sensitive to affordability, public procurement, biosimilar availability, and continuity of specialty care. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine high clinical standards with strict pricing and health technology assessment scrutiny, while Russia presents access variability tied to reimbursement coverage, local supply dynamics, and regulatory conditions.

China is accelerating biologics and biosimilars through regulatory reform, domestic innovation, and broader hospital access, while India is a major growth market for cost-effective therapies, biosimilars, and local manufacturing. Japan remains a sophisticated market with strong specialty care, high regulatory standards, and an aging population that influences autoimmune and inflammatory disease management. Australia benefits from structured public reimbursement and evidence-based access pathways, and South Korea combines advanced healthcare infrastructure with competitive biosimilar development, high digital health adoption, and export-oriented biopharmaceutical capabilities.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated mechanisms of action, validated biomarkers, and patient segmentation strategies that improve outcomes beyond established biologics and conventional disease-modifying therapies. Organizations competing in mature categories need biosimilar-aware lifecycle planning, including device innovation, adherence support, real-world evidence generation, and clear positioning for patients who fail, relapse on, or cannot tolerate first-line therapies.

Commercial success will depend on early payer engagement, robust pharmacoeconomic evidence, scalable patient assistance programs, and region-specific access strategies aligned with local reimbursement rules and clinical practice patterns. Leaders should also invest in AI governance, diverse clinical trial recruitment, supply chain resilience, cold-chain reliability, and post-marketing surveillance to strengthen trust with regulators, clinicians, payers, and patients.

Research Methodology

This executive summary is developed through a structured research methodology that triangulates regulatory approvals, clinical trial registries, peer-reviewed literature, health technology assessment outputs, public health sources, treatment guidelines, pharmacovigilance updates, and market access intelligence. Sources commonly assessed include the FDA, EMA, national regulatory agencies, ClinicalTrials.gov, WHO-linked public health data, OECD health indicators, and leading rheumatology, dermatology, neurology, endocrinology, and gastroenterology guidance.

The analysis evaluates therapy class dynamics, disease-area demand signals, regional access conditions, competitive positioning, pricing pressure, pipeline maturity, biosimilar penetration, regulatory developments, safety trends, and evidence-generation requirements. Findings are synthesized to identify durable market drivers, constraints, and strategic implications for stakeholders across the autoimmune disease drugs value chain, while avoiding unsupported market sizing or forecasting assumptions.

Conclusion

The autoimmune disease drugs market is entering a more competitive and evidence-driven phase, where scientific innovation must be matched by access, safety, affordability, and real-world performance. Biologics and targeted small molecules will continue to transform outcomes across immune-mediated disorders, while biosimilars, health technology assessment scrutiny, and payer controls will reshape pricing, reimbursement, and treatment sequencing.

Organizations that combine precision immunology, AI-enabled development, strong pharmacovigilance, differentiated delivery formats, and localized market access strategies will be best positioned to strengthen performance. The most durable opportunities will emerge in therapies that demonstrate sustained disease control, improved quality of life, convenient administration, safety confidence, and measurable value across diverse healthcare systems.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Autoimmune Disease Drugs Market, by Drug Class
7.1. Biologics
7.1.1. Fusion Proteins
7.1.2. Monoclonal Antibodies
7.1.3. Peptides
7.2. Biosimilars
7.3. Small Molecules
8. Autoimmune Disease Drugs Market, by Mechanism Of Action
8.1. B Cell Depleting Agents
8.2. Il Inhibitors
8.2.1. Il17 Inhibitors
8.2.2. Il23 Inhibitors
8.2.3. Il6 Inhibitors
8.3. Jak Inhibitors
8.3.1. Jak1 Inhibitors
8.3.2. Jak1/2 Inhibitors
8.3.3. Jak3 Inhibitors
8.4. Tnf Inhibitors
9. Autoimmune Disease Drugs Market, by Route Of Administration
9.1. Oral
9.1.1. Capsule
9.1.2. Solution
9.1.3. Tablet
9.2. Parenteral
9.2.1. Intravenous
9.2.2. Subcutaneous
10. Autoimmune Disease Drugs Market, by Indication
10.1. Inflammatory Bowel Disease
10.1.1. Crohn's Disease
10.1.2. Ulcerative Colitis
10.2. Lupus
10.3. Multiple Sclerosis
10.4. Psoriasis
10.4.1. Plaque Psoriasis
10.4.2. Psoriatic Arthritis
10.5. Rheumatoid Arthritis
11. Autoimmune Disease Drugs Market, by End User
11.1. Clinics
11.2. Homecare Settings
11.3. Hospitals
12. Autoimmune Disease Drugs Market, by Distribution Channel
12.1. Offline
12.2. Online
13. Asia-Pacific Autoimmune Disease Drugs Market
14. North America Autoimmune Disease Drugs Market
15. Latin America Autoimmune Disease Drugs Market
16. Europe Autoimmune Disease Drugs Market
17. Middle East Autoimmune Disease Drugs Market
18. Africa Autoimmune Disease Drugs Market
19. ASEAN Autoimmune Disease Drugs Market
20. GCC Autoimmune Disease Drugs Market
21. European Union Autoimmune Disease Drugs Market
22. BRICS Autoimmune Disease Drugs Market
23. G7 Autoimmune Disease Drugs Market
24. NATO Autoimmune Disease Drugs Market
25. United States Autoimmune Disease Drugs Market
26. Canada Autoimmune Disease Drugs Market
27. Mexico Autoimmune Disease Drugs Market
28. Brazil Autoimmune Disease Drugs Market
29. United Kingdom Autoimmune Disease Drugs Market
30. Germany Autoimmune Disease Drugs Market
31. France Autoimmune Disease Drugs Market
32. Russia Autoimmune Disease Drugs Market
33. Italy Autoimmune Disease Drugs Market
34. Spain Autoimmune Disease Drugs Market
35. China Autoimmune Disease Drugs Market
36. India Autoimmune Disease Drugs Market
37. Japan Autoimmune Disease Drugs Market
38. Australia Autoimmune Disease Drugs Market
39. South Korea Autoimmune Disease Drugs Market
40. Competitive Landscape
40.1. Market Concentration Analysis, 2025
40.1.1. Concentration Ratio (CR)
40.1.2. Herfindahl Hirschman Index (HHI)
40.2. Recent Developments & Impact Analysis, 2025
40.3. Product Portfolio Analysis, 2025
40.4. Benchmarking Analysis, 2025
41. Company Profiles
41.1. Abbott Laboratories
41.2. Astellas Pharma Inc.
41.3. AstraZeneca PLC
41.4. Baxter International, Inc.
41.5. Bayer AG
41.6. Biocon Limited
41.7. Bioton S.A.
41.8. Boehringer Ingelheim International GmbH
41.9. Bristol-Myers Squibb Company
41.10. Eli Lilly and Company
41.11. Eva Pharma
41.12. GlaxoSmithKline PLC
41.13. Glenmark Pharmaceuticals Limited
41.14. Gulf Pharmaceutical Industries (Julphar)
41.15. Johnson & Johnson Services, Inc.
41.16. Lupin Limited
41.17. MannKind Corporation
41.18. Merck & Co., Inc.
41.19. MJ Biopharm Pvt. Ltd.
41.20. Novartis AG
41.21. Novo Nordisk A/S
41.22. Oramed Pharmaceuticals Inc.
41.23. Pfizer Inc.
41.24. Sanofi S.A.
41.25. Takeda Pharmaceutical Company Limited
41.26. Tonghua Dongbao Pharmaceutical Co., Ltd.
41.27. Viatris Inc.
41.28. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 15. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 23. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 25. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. SPAIN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. CHINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. INDIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. JAPAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. SOUTH KOREA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL FUSION PROTEINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL FUSION PROTEINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL PEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL PEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL BIOSIMILARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL B CELL DEPLETING AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL B CELL DEPLETING AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL B CELL DEPLETING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL IL INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL IL INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL IL INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL IL17 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL IL17 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL IL17 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL IL23 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL IL23 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL IL23 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL IL6 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL IL6 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL IL6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL JAK INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL JAK INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL JAK INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL JAK1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL JAK1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL JAK1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL JAK1/2 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL JAK1/2 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL JAK1/2 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL JAK3 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL JAK3 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL JAK3 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL TNF INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL TNF INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL CAPSULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL CAPSULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL SOLUTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL SOLUTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL SOLUTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL TABLET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL TABLET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL CROHN'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL CROHN'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL CROHN'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL LUPUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL LUPUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL LUPUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL PSORIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL PSORIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL PLAQUE PSORIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL PLAQUE PSORIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL PLAQUE PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL PSORIATIC ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL PSORIATIC ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL PSORIATIC ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 139. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 140. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 141. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 142. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 143. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 144. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 145. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 146. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 147. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 148. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 149. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 150. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
TABLE 151. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 152. NORTH AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 153. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 154. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 155. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 156. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 157. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 158. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 159. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 160. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 161. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 162. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 163. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 164. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
TABLE 165. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 166. LATIN AMERICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 167. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 168. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 169. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 170. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 171. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 172. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 173. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 174. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 175. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 176. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 177. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 178. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
TABLE 179. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 180. EUROPE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 181. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 182. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 183. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 184. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 185. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 186. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 187. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 188. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 189. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 190. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 191. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 192. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
TABLE 193. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 194. MIDDLE EAST AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 195. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 196. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 197. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 198. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 199. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 200. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 201. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 202. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 203. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 204. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 205. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 206. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
TABLE 207. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 208. AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 209. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 210. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 211. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 212. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 213. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 214. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 215. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 216. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 217. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 218. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 219. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 220. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
TABLE 221. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 222. ASEAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 223. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 224. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 225. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 226. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 227. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 228. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 229. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 230. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 231. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 232. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 233. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 234. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
TABLE 235. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 236. GCC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 240. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 241. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 243. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 244. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 245. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 246. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 247. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 248. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
TABLE 249. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 250. EUROPEAN UNION AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 251. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 252. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 253. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 254. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 255. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 256. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 257. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 258. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 259. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 260. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 261. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 262. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
TABLE 263. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 264. BRICS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 265. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 266. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 267. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 268. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 269. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 270. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 271. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 272. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 273. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 274. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 275. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 276. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
TABLE 277. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 278. G7 AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 279. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 280. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 281. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 282. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 283. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 284. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 285. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 286. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 287. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 288. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 289. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 290. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
TABLE 291. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 292. NATO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 293. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 294. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 295. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 296. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 297. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 298. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 299. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 300. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 301. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 302. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 303. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 304. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
TABLE 305. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 306. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 307. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 308. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 309. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 310. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 311. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 312. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 313. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 314. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 315. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 316. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 317. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 318. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
TABLE 319. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 320. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 321. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 322. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 323. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 324. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 325. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 326. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 327. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 328. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 329. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 330. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 331. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 332. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
TABLE 333. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 334. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 335. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 336. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 337. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 338. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 339. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-2032 (USD MILLION)
TABLE 340. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
TABLE 341. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 342. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 343. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 344. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 345. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
TABLE 346. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY PSORIASIS, 2018-2032 (USD MILLION)
TABLE 347. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 348. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 349. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 350. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 351. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 352. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 353. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IL INHIBITORS, 2018-

Companies Mentioned

The companies featured in this Autoimmune Disease Drugs market report include:
  • Abbott Laboratories
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Bayer AG
  • Biocon Limited
  • Bioton S.A.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Eva Pharma
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Gulf Pharmaceutical Industries (Julphar)
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • MannKind Corporation
  • Merck & Co., Inc.
  • MJ Biopharm Pvt. Ltd.
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages199
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 135.64 Billion
Forecasted Market Value ( USD ) by 2032 $ 222.19 Billion
Compound Annual Growth Rate8.4%
Regions CoveredGlobal
No. of Companies Mentioned29

Related Topics

Related Reports

Autoimmune Disease Therapeutics Market by Therapeutic Types, Disease Type, Route of Administration, Therapeutic Application, End-User - Global Forecast 2026-2032 - Product Image

Autoimmune Disease Therapeutics Market by Therapeutic Types, Disease Type, Route of Administration, Therapeutic Application, End-User - Global Forecast 2026-2032

  • Report
  • 192 Pages
  • Global
From
Selective Immunosuppressants Market - Global Forecast 2025-2030 - Product Image

Selective Immunosuppressants Market - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Autoimmune Disease Therapeutics - Global Strategic Business Report - Product Image

Autoimmune Disease Therapeutics - Global Strategic Business Report

  • Report
  • 368 Pages
  • Global
From
Methotrexate Drugs - Global Strategic Business Report - Product Image

Methotrexate Drugs - Global Strategic Business Report

  • Report
  • 564 Pages
  • Global
From
JAK Inhibitors - Competitive Landscape, 2026 - Product Image

JAK Inhibitors - Competitive Landscape, 2026

  • Report
  • 180 Pages
  • Global
From

About the Autoimmune Disease Drug Market

The Autoimmune Disease Drug market is a subset of the Immune Disorders Drugs market, which focuses on treatments for diseases caused by an overactive immune system. These drugs are used to reduce inflammation, suppress the immune system, and prevent the body from attacking its own tissues. Common autoimmune diseases include rheumatoid arthritis, psoriasis, lupus, and multiple sclerosis. Autoimmune Disease Drugs are typically divided into two categories: biologics and small molecules. Biologics are large, complex molecules derived from living organisms, while small molecules are chemically synthesized. Both types of drugs are used to treat autoimmune diseases, but biologics are more effective and have fewer side effects. The Autoimmune Disease Drug market is highly competitive, with many companies developing and marketing drugs for the treatment of autoimmune diseases. Some of the major players in the market include AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Roche. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.